Agios Pharmaceuticals will present Phase 3 trial results for mitapivat in sickle cell disease at EHA 2026.
Quiver AI Summary
Agios Pharmaceuticals announced that detailed results from its Phase 3 RISE UP trial of mitapivat in patients with sickle cell disease will be featured in a prominent session at the upcoming European Hematology Association Congress (EHA 2026) in Stockholm from June 11-14. This trial demonstrated significant improvements in hemoglobin levels and reductions in hemolysis markers, addressing the urgent need for new therapies for this condition. Additionally, long-term data from another trial, ENERGIZE, showed sustained hemoglobin improvements in patients with thalassemia receiving mitapivat. Agios will host an investor conference call and webcast on June 13 to discuss these findings further. The company emphasizes the transformative potential of mitapivat for treating rare blood disorders, contributing to ongoing advancements in patient care.